Small-cap stock under ₹25 jumps 5% after THIS update on rights issue
Infibeam Avenues said its Rights Issue Committee will meet on 19 June 2025 to consider and approve various terms of the rights issue. It will discuss and finalise rights issue record date, price, entitlement ratio and other terms.
'... the meeting of the Rights Issue Committee is scheduled to be held on Thursday, June 19, 2025 inter alia to consider discuss and approve various terms and conditions of the Rights Issue including determination of the Rights Issue price, Record Date and Rights Entitlement ratio and other matters incidental or connected therewith and to consider other business items, if any,' Infibeam Avenues said in a regulatory filing on June 16.
Earlier on June 09, Infibeam Avenues said its Rights Issue Committee at its meeting considered and approved the Draft Letter of Offer in relation to the Rights Issue of the company to be filed with BSE and National Stock Exchange of India (NSE) for their in-principle approvals.
The board of directors of Infibeam Avenues on May 9 had approved raising of funds through issue of equity shares having face value of Re 1 for an aggregate amount of ₹ 700 crores on Rights Issue.
Infibeam Avenues share price has gained 20% in one month, and rallied 26% in three months. However, the small-cap stock has fallen 13% on a year-to-date (YTD) basis, and has dropped 27% in one year. Infibeam Avenues shares have delivered strong returns over the long term, as the stock has jumped 55% in two years and 85% in five years.
At 3:05 PM, Infibeam Avenues share price was trading 3.53% higher at ₹ 22.60 apiece on the BSE.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
12 minutes ago
- Business Standard
Brigade Hotel IPO fully subscribed on Day 2, retail investors lead demand
Brigade Hotel Ventures IPO Day 2 subscription status: The initial public offering (IPO) of hotel developer Brigade Hotel Ventures has entered the second day of bidding and has received a lacklustre response from the investors so far. The mainline offering has received bids for 52.25 million shares, against 51.19 million equity shares on offer, leading to a subscription of only 1.02 times at 2 PM on Friday, showed NSE data. The retail investors subscribed about 4.06 times the quota reserved for them, and the non-institutional investors (NIIs) portion was booked only 77 per cent. However, the qualified institutional buyers (QIBs) subscribed only 8 per cent. Ahead of the issue, the company raised ₹324.7 crore from anchor investors. The company allocated 36 million equity shares to 17 anchor investors at the upper price end of the price band of ₹85 to ₹90 per share, according to the exchange filing. Brigade Hotel IPO GMP On the second day of subscription, the unlisted shares of Brigade Hotel Ventures were trading at ₹96 per share, commanding a grey market premium (GMP) of only ₹6 or 6.7 per cent compared to the upper end price of ₹90, according to the sources tracking unofficial markets. Brigade Hotel IPO Review According to analysts at Anand Rathi Research, with a strong emphasis on asset ownership and operational oversight, Brigade Hotel Ventures has consistently demonstrated high levels of operating efficiency. Its affiliation with the reputed Brigade Group provides it with the advantage of strong parentage, deep real estate expertise, and brand credibility. "At the upper price band, the company is valued at P/E of 160x to its FY25 earnings, EV/Ebitda of 25.3x and market cap of ₹3,418.4 crore post issue of equity shares. We believe that the IPO is fully priced and recommend a Subscribe- Long-term rating to the IPO," the brokerage said. READ MORE Brigade Hotel IPO details Brigade Hotel IPO comprises a fresh issue of 84.4 million equity shares and no offer for sale (OFS) component. The mainline issue will close for public subscription on Monday, July 28. The basis of allotment of shares is likely to be finalised on Tuesday, July 29. Brigade Hotel Ventures IPO will be listed on the bourses, BSE and NSE, tentatively on Thursday, July 31. A retail investor would need a minimum investment amount of ₹14,940 to bid for at least one lot at the upper price band. Retail investors can bid for a maximum of 13 lots or 2,158 shares, amounting to ₹1,94,220. Kfin Technologies is the registrar of the issue. JM Financial and ICICI Securities are the book-running lead managers.
&w=3840&q=100)
Business Standard
40 minutes ago
- Business Standard
Nestle shares slip 7% in two days of posting Q1; what should investors do?
Nestle India Q1 results review: The fast-moving consumer goods (FMCG) major Nestle shares slipped 2 per cent on Friday, logging an intra-day low of ₹2,269.85 per share on the BSE. The stock fell nearly 7 per cent in two days after the company posted its Q1 numbers on Thursday, during market hours. At 9:40 AM, Nestle share price was trading 0.85 per cent lower at ₹2,300.4 per share on BSE. In comparison, BSE Sensex was down 0.35 per cent at 81,898.93. The market capitalisation of the company stood at ₹2,22,064.68 crore. Nestle Q1FY26 results Nestle, in the first quarter of FY26 (Q1FY26), reported a 13 per cent decline in the consolidated net profit Y-o-Y to ₹646.6 crore, as compared to ₹746.6 crore. However, its revenue from operations grew 5.8 per cent to ₹5,096 crore, from ₹4,814 crore a year ago. The company reported an Earnings before interest, tax, depreciation, and amortisation (Ebitda) at ₹34.2 crore, as compared to ₹21.3 crore, up 60.3 per cent Y-o-Y. However, Ebitda margins stood at 24.8 per cent, as against 26.5 per cent. Brokerage view on Nestle India Most brokerages have cut their target price on Nestle India stock on higher inflation concerns, and elevated depreciation/finance costs due to higher capital expenditure. ICICI Securities has maintained a 'Hold' on Nestle and has cut the target to ₹2,400 per share from ₹2,500. Nestle reported a stable quarter, according to the brokerage; however, the largest category, milk products and nutrition, appeared to be the problem child. E-commerce salience at 12.5 per cent of revenue is good and could create a material unlocking opportunity if executed well, noted ICICI Securities. The brokerage said it will remain watchful of new growth vectors under Manish Tiwary, new CMD, effective August 1. 'Nestle India requires a strategy and execution refresh,' the brokerage note read. Nuvama Institutional Equities has maintained a 'Buy' rating, but has cut the target to ₹2,820 per share from ₹2,825. The brokerage also lowered its FY26E/27E earnings per share (EPS) estimates by 6.8 per cent/4.1 per cent, as its sees depreciation/finance cost to remain elevated due to higher capex. Motilal Oswal maintained a 'Neutral' rating with a target of ₹2,400 per share. According to the brokerage, going forward, the volume growth is expected to be in low single digits. Further, even though the capacity expansion will drive long-term growth, short-term margin pressure is expected to stay. Macquaire also continued with a 'Neutral' rating on the stock and cut the target to ₹2,250 per share from ₹2,375, according to reports. The global brokerage sees near-term growth headwinds for Nestle as management commentary suggested milk and nutrition sales, the largest category of the company, are yet to recover and sees benign coffee prices hurting pricing growth in the beverages segment ahead.
&w=3840&q=100)
Business Standard
40 minutes ago
- Business Standard
Mukul Agrawal portfolio stock up 87% from April; what's behind the rally?
Tatva Chintan Pharma Chem share price today Shares of Tatva Chintan Pharma Chem hit a 52-week high of ₹1,139, as they surged 12 per cent on the BSE in Friday's intra-day trade in an otherwise weak market. A sharp surge in stock price after the company reported healthy earnings for the quarter ended June 2025 (Q1FY26). The stock price of the smallcap specialty chemicals surpassed its previous high of ₹1,101.40 touched on September 25, 2024. It has zoomed by 87 per cent from its 52-week low of ₹610 hit on April 7, 2025. At 09:40 AM; Tatva Chintan Pharma Chem was trading 10 per cent higher at ₹1,119.15, as compared to 0.35 per cent decline in the BSE Sensex. Q1 results - Tatva Chintan Pharma Chem For the April to June 2025 quarter (Q1FY26), Tatva Chintan Pharma Chem reported 33.7 per cent year-on-year (YoY) jump in consolidated profit after tax at ₹6.65 crore. Revenue from operations grew 10.8 per cent at ₹116.86 crore. Earnings before interest, taxes, depreciation, and amortization (EBITDA) grew 37.4 per cent YoY at ₹17.33 crore; margins improvement 280 bps at 14.8 per cent. The company manufactures Structure Directing Agents (SDA), Phase Transfer Catalysts, Electrolyte Salts for Super Capacitor Batteries and Pharma & Agro Intermediates and Specialty Chemicals. Trends in specialty chemicals landscape The Indian chemical industry got advantage vs China due to Trust deficit between China and the US; stringent environmental regulations since 2015 and large-scale shutdowns in China; customers preference to de-risk the supply chain led to China+1 policy; geopolitical shift after the outbreak of Covid-19 and increased cost of labour. With an increasing awareness of the ill effects of certain chemicals on humans and the environment, there is a growing trend in the chemicals industry to shift towards what is known as 'green' chemicals or more accurately sustainable chemistry. Meanwhile, China holds 39% share in the global chemical industry of which exportable specialty chemicals accounts for ~15-17 per cent while India accounts for merely 1-2 per cent indicating widespread opportunity. The spillover impact of China's declining competitiveness has set the stage for India to intensify its effort to capture larger market share, the company said. Meanwhile, during FY 25, one of the major products of the company SDA (Structure Directing Agents) saw moderation in offtake from its major export destination which is China. Due to higher adoption of LNG Powered trucks by Chinese companies, the company saw substantial decline in SDA demand from Chinese consumers. Further, the Group will be entering into the commercial phase of new products in FY 26 and offtake of new products will be crucial for improvement of business risk profile, Crisil Ratings said in its rationale. Mukul Mahavir Agrawal holds over 1 per cent holding in Tatva Chintan Pharma Chem Investor Mukul Mahavir Agrawal held 300,000 equity shares or 1.28 per cent stake in Tatva Chintan Pharma Chem at the end of June 2025 quarter, the shareholding pattern data shows. Mukul Agrawal held NIL or less than 1 per cent holding in the company at the end of March 2025 quarter, the data shows. According to information available, Mukul Mahavir Agrawal holds over 1 per cent stake in other notable listed companies, including BSE, Neuland Laboratories, Radico Khaitan, Nuvama Wealth Management, PTC Industries and LT Foods.
